TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19060425

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (5 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 100
Study: 16795983

Group type: EXPERIMENTAL
Intervention: Tumor vaccine
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (adjuvant treatment only)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: DTH response positive patients (from tumor vaccine group)
Number of subjects: 67
Study: 14515287

Group type: EXPERIMENTAL
Intervention: Postoperative portal vein infusion (PVI) of 5‐fluorouracil (5‐FU) (1 g 5‐FU plus 5000 units heparin in 1 litre 5 per cent dextrose infused over each 24‐h period for 7 days)
Number of subjects: 3583

Group type: COMPARATOR
Intervention: Radiotherapy (timing not specified)
Number of subjects: 3583

Group type: EXPERIMENTAL
Intervention: Colonic cancer
Number of subjects: 3583

Group type: COMPARATOR
Intervention: Rectal cancer
Number of subjects: 3583
Study: 11113418

Group type: EXPERIMENTAL
Intervention: Mechanical force of injection at 90 minutes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall intervention (hand injection)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hand injections
Number of subjects: 0
Study: 8736564

Group type: EXPERIMENTAL
Intervention: Frontal lesions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temporal lesions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study: 1561683

Group type: EXPERIMENTAL
Intervention: Monosialoganglioside
Number of subjects: 792

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 792
Study: 6229319

Group type: EXPERIMENTAL
Intervention: gallamine (0.29 mg X kg‐1)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: d‐tubocurarine (0.04 mg X kg‐1)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: metocurine (0.014 mg X kg‐1)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: pancuronium (0.007 mg X kg‐1)
Number of subjects: 58

Group type: COMPARATOR
Intervention: normal saline (control)
Number of subjects: 58
Study: 31541422

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 29145548

Group type: EXPERIMENTAL
Intervention: Supported Discharge Team
Number of subjects: 183

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 183
Study: 26915605

Group type: EXPERIMENTAL
Intervention: Nefiracetam 900 mg/day for 12 weeks
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 24197880

Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF test
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Ziehl‐Neelsen smear
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: MGIT culture
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF test with vortexing step
Number of subjects: 379
Study: 20946966

Group type: EXPERIMENTAL
Intervention: Clofarabine (Clo) + Fludarabine (Flu) 10:30 mg/m²
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Clofarabine (Clo) 40 mg/m²
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Clofarabine (Clo) 20:20 mg/m²
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Clofarabine (Clo) 30:10 mg/m²
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Single-agent Clo 40 mg/m²
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 51
Study: 19273465

Group type: EXPERIMENTAL
Intervention: 15-mg nicotine replacement therapy (NRT) transdermal patch for 8 weeks with usual care support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 15-mg nicotine replacement therapy (NRT) transdermal patch for 8 weeks with weekly support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study: 16731880

Group type: EXPERIMENTAL
Intervention: Internet-based psychosocial intervention (10-session manual-guided support group + 12 additional online sessions)
Number of subjects: 66

Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 66
Study: 14760368

Group type: EXPERIMENTAL
Intervention: Mailed family history data risk assessment model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetic nurse specialist assessment model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both models of service
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased cancer worry
Number of subjects: 0

Group type: COMPARATOR
Intervention: Novel community service
Number of subjects: 0
Study: 11399339

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 199
Study: 9292621

Group type: EXPERIMENTAL
Intervention: Linopirdine (LPD) 40 mg TID for 4 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo TID for 4 weeks
Number of subjects: 24
Study: 8328789

Group type: EXPERIMENTAL
Intervention: Spiramycin (1 g, orally, twice daily for 14 days)
Number of subjects: 367

Group type: COMPARATOR
Intervention: Doxycycline (100 mg, orally, twice daily for 14 days)
Number of subjects: 367
Study: 2894730

Group type: EXPERIMENTAL
Intervention: Unsaturated fatty acids (linoleic acid and gamma-linolenic acid)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 185885

Group type: EXPERIMENTAL
Intervention: Noradrenaline (6 X 10(‐6) mol/1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Isopropylnoradrenaline (6 X 10(‐6) mol/1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Basal medium (no lipolytic agents)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Phentolamine (13 mmol/1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Meritene (after re-feeding for one day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Isopropylnoradrenaline (after re-feeding)
Number of subjects: 8
Study: 30132785

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 40,000 units subcutaneously weekly up to three doses or until ICU discharge
Number of subjects: 606

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 606
Study: 28214248

Group type: EXPERIMENTAL
Intervention: Fruit intervention (changes to convenience, visibility, and attractiveness of fruit in lunchrooms for 6 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no changes made, offered Smarter Lunchrooms training post-intervention)
Number of subjects: 10
Study: 26078323

Group type: EXPERIMENTAL
Intervention: Killed whole‐cell oral cholera vaccine (OCV)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study: 23919622

Group type: EXPERIMENTAL
Intervention: ART plus FutureLife porridge nutritional supplement (NS) (388 kcal/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: ART alone (Controls)
Number of subjects: 36
Study: 22033544

Group type: EXPERIMENTAL
Intervention: Drained group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-drained group
Number of subjects: 60
Study: 19401546

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Epirubicin, and 5-Fluorouracil (CEF)
Number of subjects: 710

Group type: COMPARATOR
Intervention: Cyclophosphamide, Methotrexate, and 5-Fluorouracil (CMF)
Number of subjects: 710
Study: 17942469

Group type: EXPERIMENTAL
Intervention: Including Intent to Attend as a covariate in mixed-effects outcome analyses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not including Intent to Attend as a covariate in mixed-effects outcome analyses
Number of subjects: 0
Study: 15058405

Group type: EXPERIMENTAL
Intervention: Oral hygiene care regimen
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pre-test OAG scores
Number of subjects: 30

Group type: COMPARATOR
Intervention: Post-test OAG scores
Number of subjects: 30
Study: 11273790

Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol (10(‐9)‐10(‐4)m) administered after oxygen (FiO(2)1.0)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nebulised saline
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol (10(‐9)‐10(‐4)m) administered after hypoxic gas mixture (FiO(2)0.15)
Number of subjects: 12
Study: 9394634

Group type: EXPERIMENTAL
Intervention: Competition introduced early in training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Competition introduced late in training
Number of subjects: 0

Group type: COMPARATOR
Intervention: No competition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group size and timing of competition instructions
Number of subjects: 0
Study: 7525634

Group type: EXPERIMENTAL
Intervention: Purified prostate-specific antigen (PSA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Seminal plasma (SP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Purified PSA
Number of subjects: 0
Study: 3496202

Group type: EXPERIMENTAL
Intervention: Prophylactic sclerotherapy of esophageal varices
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conservative treatment (control group)
Number of subjects: 49
Study: 29329058

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (CBASP)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Supportive psychotherapy (SP)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Both CBASP and SP
Number of subjects: 268
Study: 26933398

Group type: EXPERIMENTAL
Intervention: HMB + Whey protein (3 g/day HMB and 36.6 g/day whey protein)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: HMB (3 g/day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Whey protein (36.6 g/day)
Number of subjects: 18
Study: 25633712

Group type: EXPERIMENTAL
Intervention: 1,000 mg of 0.2% resiquimod gel (arm B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo gel (arm A)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NY‐ESO‐1 protein plus Montanide
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NY‐ESO‐1 protein plus Montanide with or without topical resiquimod
Number of subjects: 20
Study: 23074313

Group type: EXPERIMENTAL
Intervention: Continuous infusion of beta-lactam antibiotics (piperacillin-tazobactam, meropenem, ticarcillin-clavulanate)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intermittent bolus dosing of beta-lactam antibiotics (piperacillin-tazobactam, meropenem, ticarcillin-clavulanate)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Continuous infusion of beta-lactam antibiotics
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intermittent bolus dosing of beta-lactam antibiotics
Number of subjects: 60
Study: 20817548

Group type: EXPERIMENTAL
Intervention: Single pulse transcranial magnetic stimulation (TMS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paired pulse transcranial magnetic stimulation (TMS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paired pulse TMS (2 ms inter‐stimulus interval)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paired pulse TMS (15 ms inter‐stimulus interval)
Number of subjects: 0
Study: 18333937

Group type: EXPERIMENTAL
Intervention: Oxytocin + ergometrine maleate 0.25 mg + oxytocin 20 iu
Number of subjects: 48

Group type: COMPARATOR
Intervention: Oxytocin 20 iu alone
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Oxytocin + ergometrine maleate
Number of subjects: 48
Study: 16424119

Group type: EXPERIMENTAL
Intervention: Hesperetin‐7‐glucoside juice
Number of subjects: 16
Study: 14586584

Group type: EXPERIMENTAL
Intervention: Isometric contractions via electromyostimulation (EMS); 5 sets of 10 contractions (2 s on/6 s off, 1 min between sets) followed by 3 sets of 10 contractions (1 s on/1 s off, 30 s between sets).
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable (control group).
Number of subjects: 0
Study: 11780441

Group type: EXPERIMENTAL
Intervention: Mifepristone plus misoprostol
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Mifepristone
Number of subjects: 45
Study: 9257790

Group type: EXPERIMENTAL
Intervention: Inhaled lysine acetylsalicylate (LASA) 720 mg in 4 ml saline solution
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 8289617

Group type: EXPERIMENTAL
Intervention: Explosive weight training
Number of subjects: 64

Group type: COMPARATOR
Intervention: Traditional weight training
Number of subjects: 64

Group type: COMPARATOR
Intervention: Plyometric training
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study: 3527387

Group type: EXPERIMENTAL
Intervention: Clonazepam for 4 weeks
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 6
Study: 30354558

Group type: EXPERIMENTAL
Intervention: Anakinra (100 mg subcutaneously daily)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 26863265

Group type: EXPERIMENTAL
Intervention: Lower oxygen-saturation target group (85 to 89%)
Number of subjects: 2108

Group type: COMPARATOR
Intervention: Higher oxygen-saturation target group (91 to 95%)
Number of subjects: 2108

Group type: EXPERIMENTAL
Intervention: Lower oxygen-saturation target group (85 to 89%) with revised oximeters
Number of subjects: 2108

Group type: COMPARATOR
Intervention: Higher oxygen-saturation target group (91 to 95%) with revised oximeters
Number of subjects: 2108
Study: 24769399

Group type: EXPERIMENTAL
Intervention: Organic diet (at least 80% organic food)
Number of subjects: 13
Study: 22445439

Group type: EXPERIMENTAL
Intervention: Computer-based contraceptive assessment module with individually tailored health materials (n=78)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Computer-based contraceptive assessment module without tailored materials (n=76)
Number of subjects: 224
Study: 20684443

Group type: EXPERIMENTAL
Intervention: Essential oils mouthrinse
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.05% cetylpyridinium chloride mouthrinse (CPC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 0
Study: 18215565

Group type: EXPERIMENTAL
Intervention: Lengthened yellow signal timing (increased by about 1s)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Red light camera enforcement (introduced several months after yellow timing changes)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Comparison intersections (no red light cameras, yellow timing constant)
Number of subjects: 6
Study: 16513301

Group type: EXPERIMENTAL
Intervention: MF11RCE (80mg isoflavone) per day for 90 days
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo of equal design
Number of subjects: 109
Study: 12800859

Group type: COMPARATOR
Intervention: Flavoured water (0.1 g carbohydrate, Na+ 6 mmol x l(‐1))
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (Na+ 2 mmol x l(‐1))
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte solution (6.5% carbohydrate, 6.5 g carbohydrate, Na+ 21 mmol x l(‐1))
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte solution
Number of subjects: 9
Study: 10800603

Group type: EXPERIMENTAL
Intervention: 4 hours bed rest after sheath removal
Number of subjects: 51

Group type: COMPARATOR
Intervention: 6 hours bed rest after sheath removal
Number of subjects: 51
Study: 8919651

Group type: EXPERIMENTAL
Intervention: Plasma prorenin concentration in patients with proliferative retinopathy
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Serum IGF-I concentration in patients with proliferative retinopathy
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Correlation between plasma prorenin and serum IGF-I concentrations
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: IGF-I levels in relation to renal function
Number of subjects: 22
Study: 1524162

Group type: EXPERIMENTAL
Intervention: Closed suction system 'Trach Care'
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional disposable suction system
Number of subjects: 60
Study: 6435484

Group type: EXPERIMENTAL
Intervention: TTS-nitroglycerin (transdermal therapeutic system)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 2% nitroglycerin ointment (0.5 inch applied at 8 hr intervals over 10 cm2 of skin)
Number of subjects: 12
Study: 31619089

Group type: EXPERIMENTAL
Intervention: Monofilament threads
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 0
Study: 30652395

Group type: EXPERIMENTAL
Intervention: Fluorescein angiography (FA) features for PCV
Number of subjects: 95
Study: 29358716

Group type: EXPERIMENTAL
Intervention: Motivational resistance-training programme (12 weeks, 36 sessions)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Motivational resistance-training programme
Number of subjects: 47
Study: 26284816

Group type: EXPERIMENTAL
Intervention: Playworks intervention
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 24701539

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied in a single sitting divided into four sessions.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham control group (similar treatment without activating the LASER unit).
Number of subjects: 30
Study: 22374345

Group type: EXPERIMENTAL
Intervention: Stop and Go (SAG) strategy
Number of subjects: 42

Group type: COMPARATOR
Intervention: 3-days switch (3DS) strategy
Number of subjects: 42
Study: 20164251

Group type: EXPERIMENTAL
Intervention: MenACWY-CRM and Tdap
Number of subjects: 0

Group type: COMPARATOR
Intervention: MenACWY-CRM and saline placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tdap and saline placebo
Number of subjects: 0
Study: 17011662

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 443

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 443
Study: 15902372

Group type: EXPERIMENTAL
Intervention: Dipyridamole-dobutamine stress echocardiography (Dip-Dob)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Dipyridamole-atropine stress echocardiography (Dip-Atro)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Dip-Dob
Number of subjects: 127

Group type: COMPARATOR
Intervention: Dip-Atro
Number of subjects: 127
Study: 11863235

Group type: EXPERIMENTAL
Intervention: guided threat focus and reappraisal
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: safety-behavior utilization
Number of subjects: 46

Group type: COMPARATOR
Intervention: exposure only control
Number of subjects: 46
Study: 10629930

Group type: COMPARATOR
Intervention: Amiridin (80 mg daily for 10 weeks)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cerebrolysin (20 intravenous infusions of 30 ml in 150 ml of physiologic solution during 4 weeks) followed by amiridin (80 mg daily for 10 weeks)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cerebrolysin followed by amiridin
Number of subjects: 49
Study: 7771821

Group type: EXPERIMENTAL
Intervention: Hypothermic continuous blood cardioplegia and hypothermic perfusion
Number of subjects: 872

Group type: COMPARATOR
Intervention: Normothermic continuous blood cardioplegia and normothermic perfusion
Number of subjects: 872
Study: 1980310

Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Number of subjects: 5
Study: 6101934

Group type: EXPERIMENTAL
Intervention: Beta-adrenoreceptor antagonists (propranolol, oxprenolol, practolol, metoprolol, tolamolol)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 30460781

Group type: EXPERIMENTAL
Intervention: buprenorphine/naloxone
Number of subjects: 442

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 442
Study: 28976976

Group type: COMPARATOR
Intervention: 20-week prednisolone treatment
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: 32-week prednisolone treatment
Number of subjects: 868
Study: 26921548

Group type: EXPERIMENTAL
Intervention: MenACYW-D
Number of subjects: 300

Group type: COMPARATOR
Intervention: Tdap
Number of subjects: 300
Study: 24450727

Group type: EXPERIMENTAL
Intervention: Digital planimetry (DP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ruler technique (RT)
Number of subjects: 0
Study: 21829156

Group type: EXPERIMENTAL
Intervention: Low-fat diet (<20% fat)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: High-fat diet (>45% fat)
Number of subjects: 31
Study: 19744006

Group type: EXPERIMENTAL
Intervention: Ropinirole hydrochloride (REQUIP®, ADARTREL®)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pramipexole dihydrochloride (MIRAPEX®, SIFROL®)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D3 receptor subtype-selective agonists
Number of subjects: 0
Study: 17514185

Group type: EXPERIMENTAL
Intervention: Asenapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 15920715

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study: 12196433

Group type: EXPERIMENTAL
Intervention: Insulin glargine (40 mU/m2)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Regular insulin (40 mU/m2)
Number of subjects: 15
Study: 9841585

Group type: EXPERIMENTAL
Intervention: Complete Thymic Formula for 3 to 6 months
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 38
Study: 7859517

Group type: EXPERIMENTAL
Intervention: Pulse oximetry monitoring
Number of subjects: 20802
Study: 2673622

Group type: EXPERIMENTAL
Intervention: Recainam (300 to 600 mg every 8 hours)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Recainam (mean effective dosage 427 mg every 8 hours)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Recainam
Number of subjects: 20
Study: 5420207

Group type: EXPERIMENTAL
Intervention: Oxazepam (Serenid-D) in green tablets
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Oxazepam (Serenid-D) in yellow tablets
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Oxazepam (Serenid-D) in red tablets
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Physicians' assessment of phobias
Number of subjects: 48
Study: 31652347

Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ustekinumab 45 mg or 90 mg
Number of subjects: 0
Study: 29978873

Group type: EXPERIMENTAL
Intervention: Hibiscus and lemon verbena polyphenols
Number of subjects: 0
Study: 28204639

Group type: EXPERIMENTAL
Intervention: 2D RANO criteria
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Volumetric methods
Number of subjects: 148

Group type: COMPARATOR
Intervention: Volumetric methods (excluding subtraction of non-enhancing from enhancing volume)
Number of subjects: 148
Study: 26248573

Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate 110 mg b.i.d.
Number of subjects: 2782

Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate 150 mg b.i.d.
Number of subjects: 2782

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 2782